Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

204906 Complement C5b,6 Complex, Human

Complement C5b,6 Complex, Human, is a native complement complex where the nascent C5b fragment is combined with C6 to form a stable complex.

Complement C5b,6 Complex, Human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
204906
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
204906-50UG Plastic ampoule 50 μg
Description
OverviewNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8, and C9 to form the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8, and C9.
Catalogue Number204906
Brand Family Calbiochem®
References
ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
Product Information
FormLiquid
FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
Quality LevelMQ100
Applications
Biological Information
Purity≥95% by SDS-PAGE
SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Specific Activity≥2000 C5b,6H50 units/mg
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
204906-50UG 04055977219883

Documentation

Complement C5b,6 Complex, Human SDS

Title

Safety Data Sheet (SDS) 

Complement C5b,6 Complex, Human Certificates of Analysis

TitleLot Number
204906

References

Reference overview
Podack, E.R., et al. 1978. J. Immunol. 120, 1841.
Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision27-May-2008 RFH
DescriptionNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8 and C9 to from the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8 and C9.
FormLiquid
FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
Concentration Label Please refer to vial label for lot-specific concentration
SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Purity≥95% by SDS-PAGE
Specific activity≥2000 C5b,6H50 units/mg
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Toxicity Standard Handling
ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.